Blogs about: Gsk572016
Featured Blog
GSK respond to negative NICE recommendation on Tykerb
GSK have responded to the NICE recommendationi that Tyverb (lapatinib) should not be used in the NHS, except in clinical trials. The company says “we strongly believe that the wrong decision has… more →
Kinase News
GSK respond to negative NICE recommendation on Tykerb
crimsoncanary wrote 1 year ago: GSK have responded to the NICE recommendationi that Tyverb (lapatinib) should not be used in the NHS … more →
GSKs Tykerb (lapatinib) effective in advanced head and neck cancer
crimsoncanary wrote 1 year ago: Phase II data presented at the European of Medical Oncology (ESMO) show that GSK’s Tykerb (lap … more →
Tykerb receives conditional EU marketing approval for HER2 breast cancer
crimsoncanary wrote 1 year ago: GlaxoSmithKline have received a conditional marketing authorisation from the european autorities for … more →
Phase II data on lapatinib (Tykerb) presented at ASCO
crimsoncanary wrote 1 year ago: Data presented at ASCO highlight recent findings with lapatinib including: - Phase II data on Lapati … more →
Phase I dose escalation trial of Lapatinib in combination with trastuzumab
crimsoncanary wrote 1 year ago: Phase I results show that combining 1000 mg lapatinib and weekly trastuzumab is well tolerated … more →
Tykerb plus Herceptin increase PFS
crimsoncanary wrote 1 year ago: Results from a Phase III trial show that the administration of Tykerb in combination with Herceptin … more →
Lapatinib enters global early breast cancer trial
crimsoncanary wrote 1 year ago: GSK and the Breast International Group (BIG) are initiating a phase III clinical trial of Lapatinib … more →
Lapatinib demonstrates efficacy in renal cancer
crimsoncanary wrote 1 year ago: In a phase III study in renal cell carcinoma patients lapatinib displayed equivalent efficacy to hor … more →
Lapatinib safe and efficacious as First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer
crimsoncanary wrote 1 year ago: Lapatinib has demonstrated efficacy and was well tolerated as first-line therapy in ErbB2-amplified … more →
EMEA issues revised positive opinion on lapatinib in breast cancer
crimsoncanary wrote 1 year ago: The EMEA’s CHMP division has issued a revised positive opinion for lapatinib in breast cancer. … more →
Lapatinib decreases tumorigenic breast cancer stem cells
crimsoncanary wrote 1 year ago: Data presented at the 6th European Breast Cancer Conference shows tumorigenic breast cancer cells ar … more →
